<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /home/lopez/grobid/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Haptoglobin Genotype and Renal Function Decline in Type 1 Diabetes</title>
			</titleStmt>
			<publicationStmt>
				<publisher>American Diabetes Association</publisher>
				<availability status="unknown"><p>Copyright American Diabetes Association</p>
				</availability>
				<date type="published" when="2009-08-31">31 August 2009</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tina</forename><surname>Costacou</surname></persName>
							<email>costacout@edc.pitt.edu</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Epidemiology</orgName>
								<orgName type="institution">University of Pittsburgh</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>Pennsylvania</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><forename type="middle">E</forename><surname>Ferrell</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Human Genetics</orgName>
								<orgName type="institution">University of Pitts-burgh</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<country>Pennsylvania</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Demetrius</forename><surname>Ellis</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Children&apos;s Hospital of Pittsburgh</orgName>
								<orgName type="department" key="dep2">School of Medicine</orgName>
								<orgName type="institution">University of Pittsburgh</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>Pennsylvania</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Trevor</forename><forename type="middle">J</forename><surname>Orchard</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Epidemiology</orgName>
								<orgName type="institution">University of Pittsburgh</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>Pennsylvania</region>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Haptoglobin Genotype and Renal Function Decline in Type 1 Diabetes</title>
					</analytic>
					<monogr>
						<title level="j" type="main">Diabetes</title>
						<title level="j" type="abbrev">Diabetes</title>
						<idno type="ISSN">0012-1797</idno>
						<idno type="eISSN">1939-327X</idno>
						<imprint>
							<publisher>American Diabetes Association</publisher>
							<biblScope unit="volume">58</biblScope>
							<biblScope unit="issue">12</biblScope>
							<biblScope unit="page" from="2904" to="2909"/>
							<date type="published" when="2009-08-31">31 August 2009</date>
						</imprint>
					</monogr>
					<idno type="DOI">10.2337/db09-0874</idno>
					<idno type="PMID">19720796</idno>
					<idno type="PMCID">PMC2780877</idno>
					<ptr type="open-access" target="http://diabetes.diabetesjournals.org/content/58/12/2904.full.pdf" />
					<note type="submission">Received 11 June 2009 and accepted 17 August 2009.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.6.2-SNAPSHOT" ident="GROBID" when="2020-08-14T00:25+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
				<p>OBJECTIVE-Haptoglobin (Hp) binds free Hb, inhibiting Hbinduced oxidative damage. As oxidative stress has been associated with microvascular complications, we evaluated the relationship between Hp genotype and microalbuminuria, macroalbuminuria, end-stage renal disease (ESRD), and early renal function decline in type 1 diabetes. RESEARCH DESIGN AND METHODS-Participants from the Epidemiology of Diabetes Complications Study with DNA available were studied for the incidence of microalbuminuria (albumin excretion rate [AER] 20-200 g/min), macroalbuminuria (AER Ͼ200 g/min), ESRD (renal dialysis or transplantation), and renal function decline (a decline Ն30 ml/min per 1.73 m 2 from baseline estimated [by the Cockcroft-Gault equation] glomerular filtration rate [eGFR] in those with baseline eGFR Ͼ60 ml/min per 1.73 m 2). RESULTS-The proportions with the Hp 2/2, 2/1, and 1/1 genotype were 43.4, 44.4, and 12.1%, respectively. During 18 years of follow-up, the incidence of eGFR decline, microalbuminuria, macroalbuminuria, and ESRD was 42.0, 40.5, 16.7, and 12.2%, respectively. No significant univariate differences were observed by Hp genotype. However, in multivariable Cox models, an ϳtwofold increased risk was observed for the Hp 2/2 compared with the Hp 1/1 genotype for eGFR decline (hazard ratio 1.79 [95% CI 1.06-3.00]) and ESRD (2.74 [1.17-6.45]); no significant associations were observed for microalbuminuria or macroalbuminuria. CONCLUSIONS-These data suggest that although Hp genotype is not associated with albuminuria per se, it may be an independent determinant of early renal function decline and progression to ESRD. Understanding these apparent contradictory findings may provide further insight into the pathogenesis of renal disease in type 1 diabetes.</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>R</head><p>eactive oxygen species have been implicated in both the etiology and progression of diabetes complications, including nephropathy <ref type="bibr" target="#b0">(1)</ref>. However, clinical trials assessing the impact of antioxidant supplementation on micro-and macrovascular disease development have generally yielded null results <ref type="bibr" target="#b1">(2)</ref>.</p><p>It has recently been proposed that the effectiveness of an antioxidant regimen may be limited to susceptible subgroups, such as individuals with the haptoglobin (Hp) 2/2 genotype <ref type="bibr" target="#b2">(3)</ref>. Hp is an acute-phase plasma ␣ 2glycoprotein that, by binding to free Hb, inhibits Hbinduced oxidative tissue damage <ref type="bibr" target="#b3">(4)</ref>. Once bound to Hp, the Hp-Hb complex is cleared from circulation either at the liver hepatocyte or through the scavenger receptor CD163 present on monocytes and macrophages <ref type="bibr" target="#b4">(5)</ref>. In humans, two common allele classes (Hp 1 and Hp 2 ) at the Hp locus on chromosome 16q22 form three major genotypes: Hp 1/1, Hp 2/1, and Hp 2/2 <ref type="bibr" target="#b3">(4)</ref>. Substantial evidence supports a pathogenetic role of this polymorphism <ref type="bibr" target="#b5">(6)</ref>, with the Hp 1 protein allele being more efficient in preventing heme release from Hp-Hb complexes and promoting uptake by the CD163 macrophage receptor <ref type="bibr" target="#b6">(7)</ref><ref type="bibr" target="#b7">(8)</ref><ref type="bibr" target="#b8">(9)</ref> as well as the antioxidant capacity of Hp 2 allele protein product being restricted by its greater molecular mass <ref type="bibr" target="#b4">(5)</ref> and also associated with impaired reverse cholesterol transport <ref type="bibr" target="#b6">(7,</ref><ref type="bibr" target="#b9">10)</ref>. Moreover, although Hp allele distribution does not differ by diabetes status <ref type="bibr" target="#b5">(6)</ref>, the Hp 2 allele protein product increases susceptibility to vascular complications only in diabetes <ref type="bibr" target="#b10">(11,</ref><ref type="bibr" target="#b11">12)</ref>. Finally, daily vitamin E supplementation in type 2 diabetes with the Hp 2/2 genotype significantly reduced cardiovascular event risk <ref type="bibr" target="#b12">(13,</ref><ref type="bibr" target="#b13">14)</ref>.</p><p>We have previously shown that the Hp 2/2 genotype is a determinant of the risk of cardiovascular disease also in type 1 diabetes <ref type="bibr" target="#b14">(15)</ref>. In this article, we evaluated the relationship between Hp genotype and both renal damage (microalbuminuria and macroalbuminuria) and renal function (end-stage renal disease [ESRD] and early renal function decline) in type 1 diabetes (n ϭ 486).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESEARCH DESIGN AND METHODS</head><p>The Epidemiology of Diabetes Complications Study was based on a historical cohort of incident cases of childhood-onset (Ͻ17 years) type 1 diabetes, diagnosed or seen within 1 year of diagnosis <ref type="bibr">(1950 -1980)</ref> at Children's Hospital of Pittsburgh <ref type="bibr" target="#b15">(16)</ref>. The cohort has been shown to be representative of the Allegheny County, Pennsylvania, type 1 diabetes population <ref type="bibr" target="#b16">(17)</ref>. Subsequent to a first clinical assessment <ref type="bibr">(1986 -1988</ref>, when average participant age and diabetes duration were 28 and 19 years, respectively), biennial examinations were conducted for 10 years, with a further examination at 18 years. The University of Pittsburgh Institutional Review Board approved the study protocol.</p><p>Prior to each clinic visit, participants were sent questionnaires concerning demographic, health care, self-care, and medical history information. Blood pressure was measured with a random zero sphygmomanometer after a 5-min rest <ref type="bibr" target="#b17">(18)</ref>. Hypertension was defined as Ն140/90 mmHg or use of antihypertensive medication. Stable HbA 1 was measured by ion exchange chromatography (Isolab, Akron, OH) and subsequently by automated highperformance liquid chromatography (Diamat; BioRad, Hercules, CA). The two assays were highly correlated (r ϭ 0.95). HDL cholesterol was determined by a precipitation technique with a modification <ref type="bibr" target="#b18">(19)</ref> of the Lipid Research Clinics method (20). Cholesterol and triglycerides were enzymatically measured <ref type="bibr" target="#b19">(21,</ref><ref type="bibr" target="#b20">22)</ref>. Non-HDL cholesterol was calculated as total minus HDL cholesterol. White blood cell count was obtained using a counter S-plus IV and fibrinogen using a biuret colorimetric procedure and a clotting method.</p><p>Urinary albumin was measured by immunonephelometry <ref type="bibr" target="#b21">(23)</ref>, and creatinine was assayed by an Ectachem 400 Analyzer (Eastman Kodak, Rochester, NY). Microalbuminuria was defined as albumin excretion rate (AER) of 20 -200 g/min (30 -300 mg per 24 h) and macroalbuminuria as AER Ͼ200 g/min (Ͼ300 mg per 24 h) in at least 2 of 3 validated timed urine collections. In 10% of the samples, urine collections were deemed inadequate based on creatinine excretion and albumin-to-creatinine ratio was used (microalbuminuria, 0.03-0.3 mg/mg; macroalbuminuria, Ͼ0.3 mg/mg) <ref type="bibr" target="#b22">(24)</ref>. ESRD onset was defined as starting dialysis or undergoing renal transplantation. Early renal function decline was defined as the incidence of a decline of Ն30 ml/min per 1.73 m 2 from baseline estimated glomerular filtration rate (eGFR) based on the Cockcroft-Gault equation <ref type="bibr" target="#b23">(25)</ref> among participants with normal or mildly reduced renal function at study entry (stages I and II).</p><p>High molecular weight genomic DNA was isolated using the PureGene kit (Gentra Systems, Minneapolis, MN), and Hp was genotyped by an amplification method <ref type="bibr" target="#b24">(26)</ref>. Genotypes were assigned visually by comparison with controls of known genotype and in a random sample showed excellent agreement (97%) with an Eliza method <ref type="bibr" target="#b25">(27)</ref>. Statistical analysis. Nonnormally distributed variables were logarithmically transformed. Univariate associations were determined using the Student t test and <ref type="bibr" target="#b1">2</ref> or Fisher exact test, as appropriate. Cox proportional hazards models with backward elimination were constructed to assess the multivariable association between Hp genotype and the incidence of each outcome of interest adjusting for traditional risk factors (including eGFR and AER levels at study entry) and univariately significant variables. Survival time was defined as the time in years from study entry to either an incident event or censorship during the 18-year follow-up. Statistical analyses were conducted using SAS (version 9.1; SAS Institute, Cary, NC).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head><p>Of 658 study participants, DNA for Hp genotyping was available for 486 (73.9%). Compared with those without DNA available, individuals with DNA data had a shorter diabetes duration and higher HbA 1 , blood pressure, non-HDL cholesterol, serum creatinine, eGFR, and AER. The distribution of the Hp genotype was 12.1% Hp 1/1, 44.4% Hp 2/1, and 43.4% Hp 2/2. Generally, no differences were observed in participant characteristics by Hp genotype at study entry with the exception of younger age and higher non-HDL cholesterol in those with the Hp 2/2 compared with the 2/1 genotype and lower insulin dose per weight in those with the Hp 2/1 compared with the 1/1 genotype.</p><p>During 18 years of follow-up, 40.5% (n ϭ 111) developed incident microalbuminuria, 16.7% (n ϭ 62) macroalbuminuria, and 12.2% (n ϭ 58) ESRD. Moreover, 188 (42.0%) exhibited an early decline in renal function (Ն30 ml/min per 1.73 m 2 from baseline eGFR). Descriptive participant characteristics by incidence of microalbuminuria and macroalbuminuria are shown in <ref type="table" target="#tab_0">Table 1</ref> and by renal function decline Ն30 ml/min per 1.73 m 2 and ESRD incidence in <ref type="table" target="#tab_1">Table 2</ref>. Generally, incident case subjects with both microalbuminuria and macroalbuminuria were more likely to have higher levels of HbA 1 , non-HDL cholesterol, AER, and inflammatory markers compared with those who remained disease free. Incident case subjects with macroalbuminuria were also older at the time of diabetes onset compared with noncase subjects and had a greater waist-to-hip ratio.</p><p>Compared with noncase subjects, incident case subjects with early renal function decline and ESRD were older, To examine the possibility of survival bias, we stratified the cohort by diabetes diagnosis year (prior to or after 1965, wherein mortality was 40 vs. 13%, respectively). With the exception of macroalbuminuria, a trend toward higher incidence rates among the Hp 2/2 compared with the Hp 1/1 genotype was generally observed in those diagnosed after 1965 (less subject to survival bias); however, none of the stratified results were statistically significant <ref type="table" target="#tab_3">(Table 4)</ref>. Similarly, when conducting cumulative incidence analyses (including prevalent cases in outcomes), results demonstrated nonsignificantly higher rates in those carrying the Hp 2/2 compared with the Hp 1/1 genotype with the exception of macroalbuminuria <ref type="table" target="#tab_3">(Table 4</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p>In this cohort of subjects with type 1 diabetes, we failed to show an association between the Hp genotype and either microalbuminuria or macroalbuminuria incidence. However, although not univariately significant, approximately a twofold increased risk emerged for outcomes assessing renal function decline and ESRD incidence after multivariable adjustments. Previous studies assessing the association between the Hp phenotype and the presence or incidence of renal disease have produced discrepant findings. In a small, cross-sectional study of normotensive subjects with type 1 or 2 diabetes, none of those with the Hp 1/1 phenotype exhibited signs of nephropathy (0/18) compared with 27% (10/37) of those with Hp 2/1 and 34% (19/55) of those with Hp 2/2 (P Ͻ 0.02) <ref type="bibr" target="#b5">(6,</ref><ref type="bibr" target="#b26">28)</ref>. Similar results were reported from an Irish type 1 diabetes case-control study <ref type="bibr" target="#b27">(29)</ref>. Conversely, a Japanese study of individuals with a long duration (Ͼ10 years) of type 2 diabetes did not observe an increased risk associated with the common Hp phenotype (P ϭ 0.43) <ref type="bibr" target="#b28">(30)</ref>. Similarly, we were also not able to detect an association for either microalbuminuria or macroalbuminuria incidence in our cohort of individuals with a long duration of type 1 diabetes, perhaps suggesting that at a more advanced stage of diabetes, early Hp-susceptible cases of microalbuminuria and macroalbuminuria may have been excluded. Indeed, the cumulative incidence of microalbuminuria (including both prevalent cases at study entry and incident cases) appeared higher in our study among participants carrying the Hp 2 allele, although results did not reach statistical significance. However, analogous findings were not observed for the cumulative incidence of macroalbuminuria, suggesting that the Hp 2/2 genotype is not a strong determining factor for progression to macroalbuminuria.</p><p>Despite the null associations for the incidence of proteinuria, a strong relationship was noted between the Hp 2/2 genotype and the incidence of both an early decline in renal function and ESRD. Unfortunately, we are not aware of any published reports on the association between the Hp genotype and renal function decline among individuals with diabetes and thus cannot, at present, confirm these findings. However, the possibility of a factor affecting the incidence of renal dysfunction but not that of renal disease per se raises the hypothesis that these are two different disease entities, and thus factors contributing to their development may be distinct. Indeed, almost a decade ago, we suggested that in certain cases tubulopathy may precede glomerulopathy in type 1 diabetes and that even microalbuminuria may be secondary to impaired tubular reabsorption <ref type="bibr" target="#b29">(31)</ref>. More recently, research studies have shown that reductions in eGFR do occur without preceding microalbuminuria in those with diabetes <ref type="bibr" target="#b30">(32)</ref><ref type="bibr" target="#b31">(33)</ref><ref type="bibr" target="#b32">(34)</ref>. Importantly, a pathophysiological mechanism has been proposed that could account for the increased rate of renal function decline among individuals with diabetes and the 508.736 Model 1 allowed for diabetes duration, sex, smoking status, log AER, and eGFR Model 2 allowed for variables in model 1 in addition to HbA 1 , hypertension, and HDL and non-HDL cholesterol Model 3 allowed for variables in model 2 in addition to white blood cell count and fibrinogen Hp 2/2 genotype (7), based on the recognition that renal proximal tubule cells serve as a (secondary to CD163) default mechanism for clearance of the Hp-Hb complex. Because CD163-mediated clearance of the Hp-Hb complex is impaired in subjects with diabetes and the Hp 2/2 genotype, renal proximal tubule cells are used to a greater extent, resulting in a dramatic increase in iron deposition, oxidative stress, and hypertrophy. In fact, Hp 2/2 diabetic mice have been shown to display significantly increased glomerular and proximal tubular hypertrophy and greater deposition of collagen type IV, smooth muscle actin, and increased renal iron <ref type="bibr" target="#b33">(35)</ref>. Intriguingly, vitamin E administration was shown to slow diabetic renal disease progression among the Hp 2/2 but not the Hp 1/1 mice.</p><p>In conclusion, we observed an association between the Hp genotype and renal function decline in individuals with long-standing type 1 diabetes. A caveat of this study is the lack of independent replication of findings in another cohort. Nevertheless, these results raise the possibility that pharmacological administration of vitamin E, shown to reduce cardiovascular disease outcomes in those with type 2 diabetes with the Hp 2/2 genotype <ref type="bibr" target="#b12">(13)</ref><ref type="bibr" target="#b13">(14)</ref>, may also lead to reduced renal disease risk. </p></div><figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>TABLE 1</head><label>1</label><figDesc>Participant characteristics at study entry by subsequent microalbuminuria and macroalbuminuria status HbA 1 , and eGFR and lower serum creatinine. Conversely, greater diabetes duration and higher levels of diastolic blood pressure and serum creatinine but lower insulin dose per kilogram body weight and eGFR were observed in incident case subjects with ESRD compared with noncase subjects. No univariate association, however, was observed between Hp and the incidence of other renal outcomes at the 0.05 significance level. Hp genotype was also not associated with all-cause mortality (P ϭ 0.80) based on 82 (16.9%) deceased individuals.</figDesc><table><row><cell></cell><cell cols="2">Microalbuminuria</cell><cell></cell><cell cols="2">Macroalbuminuria</cell><cell></cell></row><row><cell></cell><cell>No</cell><cell>Yes</cell><cell>P</cell><cell>No</cell><cell>Yes</cell><cell>P</cell></row><row><cell>n</cell><cell>163</cell><cell>111</cell><cell></cell><cell>309</cell><cell>62</cell><cell></cell></row><row><cell>Age (years)</cell><cell>25.0 Ϯ 7.7</cell><cell>25.8 Ϯ 8.3</cell><cell>0.37</cell><cell>26.2 Ϯ 8.1</cell><cell>27.1 Ϯ 7.4</cell><cell>0.43</cell></row><row><cell>Age at onset (years)</cell><cell>8.5 Ϯ 4.2</cell><cell>8.3 Ϯ 4.1</cell><cell>0.64</cell><cell>8.2 Ϯ 4.2</cell><cell>9.3 Ϯ 3.3</cell><cell>0.02</cell></row><row><cell>Diabetes duration (years)</cell><cell>16.3 Ϯ 6.9</cell><cell>17.6 Ϯ 7.6</cell><cell>0.21</cell><cell>18.0 Ϯ 7.6</cell><cell>17.8 Ϯ 7.5</cell><cell>0.83</cell></row><row><cell>Follow-up time (years)</cell><cell>15.5 Ϯ 5.0</cell><cell>7.3 Ϯ 4.8</cell><cell cols="2">Ͻ0.0001 15.2 Ϯ 5.0</cell><cell>8.0 Ϯ 5.3</cell><cell>Ͻ0.0001</cell></row><row><cell>Female subjects</cell><cell>50.9 (83)</cell><cell>55.9 (62)</cell><cell>0.42</cell><cell>52.4 (162)</cell><cell>40.3 (25)</cell><cell>0.08</cell></row><row><cell>BMI (kg/m 2 )</cell><cell>23.1 Ϯ 3.2</cell><cell>23.2 Ϯ 3.3</cell><cell>0.70</cell><cell>23.5 Ϯ 3.4</cell><cell>23.6 Ϯ 3.1</cell><cell>0.74</cell></row><row><cell>Waist-to-hip ratio</cell><cell>0.81 Ϯ 0.06</cell><cell>0.82 Ϯ 0.06</cell><cell>0.27</cell><cell>0.81 Ϯ 0.07</cell><cell>0.84 Ϯ 0.07</cell><cell>0.002</cell></row><row><cell>Ever smokers</cell><cell>28.8 (47)</cell><cell>31.5 (35)</cell><cell>0.63</cell><cell>32.0 (99)</cell><cell>38.7 (24)</cell><cell>0.31</cell></row><row><cell>HbA 1 (%)</cell><cell>9.7 (1.4)</cell><cell>10.8 (1.8)</cell><cell cols="2">Ͻ0.0001 10.0 (1.6)</cell><cell>11.1 (2.0)</cell><cell>0.0002</cell></row><row><cell>Insulin dose per weight*</cell><cell>0.81 (0.65-0.95)</cell><cell>0.80 (0.66-0.95)</cell><cell>0.77</cell><cell>0.80 (0.63-0.94)</cell><cell>0.80 (0.60-0.98)</cell><cell>0.97</cell></row><row><cell cols="2">Systolic blood pressure (mmHg) 106.9 Ϯ 10.7</cell><cell>109.1 Ϯ 10.3</cell><cell cols="2">0.10 108.8 Ϯ 11.4</cell><cell>110.7 Ϯ 12.9</cell><cell>0.24</cell></row><row><cell cols="2">Diastolic blood pressure (mmHg) 67.9 Ϯ 8.4</cell><cell>69.8 Ϯ 7.8</cell><cell>0.05</cell><cell>69.5 Ϯ 9.1</cell><cell>70.8 Ϯ 9.1</cell><cell>0.31</cell></row><row><cell>Hypertension</cell><cell>3.7 (6)</cell><cell>3.6 (4)</cell><cell>1.00 †</cell><cell>5.5 (17)</cell><cell>9.7 (6)</cell><cell>0.21</cell></row><row><cell>HDL cholesterol (mg/dl)</cell><cell>55.2 Ϯ 12.1</cell><cell>54.0 Ϯ 9.8</cell><cell>0.37</cell><cell>54.5 Ϯ 11.4</cell><cell>56.1 Ϯ 11.9</cell><cell>0.38</cell></row><row><cell>Non-HDL cholesterol (mg/dl)</cell><cell>116.0 Ϯ 25.5</cell><cell>128.1 Ϯ 34.3</cell><cell cols="2">0.002 122.9 Ϯ 30.2</cell><cell>141.1 Ϯ 43.2</cell><cell>0.002</cell></row><row><cell>ACE/ARB use</cell><cell>1.3 (2)</cell><cell>0.9 (1)</cell><cell>1.00 †</cell><cell>1.0 (3)</cell><cell>1.7 (1)</cell><cell>0.52 †</cell></row><row><cell>Serum creatinine (mg/dl)*</cell><cell>0.80 (0.70-1.0)</cell><cell>0.80 (0.60-0.90)</cell><cell>0.16</cell><cell>0.80 (0.70-1.0)</cell><cell>0.90 (0.70-1.0)</cell><cell>0.39</cell></row><row><cell>eGFR by Cockcroft-Gault</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>(ml/min per 1.73 m 2 )</cell><cell>121.1 Ϯ 37.8</cell><cell>124.6 Ϯ 38.7</cell><cell cols="2">0.46 120.9 Ϯ 37.1</cell><cell>125.0 Ϯ 43.5</cell><cell>0.44</cell></row><row><cell>AER (g/min)*</cell><cell>7.2 (5.1-10.1)</cell><cell>9.0 (6.2-11.6)</cell><cell cols="2">0.004 19.2 (5.9-16.1)</cell><cell>23.5 (9.5-71.3)</cell><cell>Ͻ0.0001</cell></row><row><cell>White blood cell count ϫ</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>10 3 /mm 2 *</cell><cell>5.6 (4.8-6.6)</cell><cell>6.1 (5.2-7.2)</cell><cell>0.02</cell><cell>5.8 (5.1-7.0)</cell><cell>6.7 (5.2-8.0)</cell><cell>0.005</cell></row><row><cell>Fibrinogen (mg/dl)*</cell><cell cols="6">250.0 (200.0-300.0) 265.0 (220.0-300.0) 0.12 250.0 (210.0-305.0) 270.0 (240.0-310.0) 0.06</cell></row><row><cell>Hp genotype</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>1/1</cell><cell>77.4 (24)</cell><cell>22.6 (7)</cell><cell></cell><cell>81.4 (35)</cell><cell>18.6 (8)</cell><cell></cell></row><row><cell>2/1</cell><cell>55.5 (71)</cell><cell>44.5 (57)</cell><cell></cell><cell>84.8 (145)</cell><cell>15.2 (26)</cell><cell></cell></row><row><cell>2/2</cell><cell>59.1 (68)</cell><cell>40.9 (47)</cell><cell>0.08</cell><cell>82.2 (129)</cell><cell>17.8 (28)</cell><cell>0.77</cell></row></table><note>Data are percent (n) or means Ϯ SD unless otherwise indicated. The sample size for ACE/angiotensin receptor blocker medications was 270 for the outcome of microalbuminuria (159 noncases and 111 incident cases) and 362 for the outcome of macroalbuminuria (302 noncases and 60 incident cases). *The Wilcoxon two-sample test was used for nonnormally distributed variables; data are median (interquartile range). †Fisher exact test. ARB, angiotensin receptor blocker.with higher systolic blood pressure, non-HDL cholesterol, AER, and inflammatory marker levels and lower HDL cholesterol. Incident case subjects with early renal func- tion decline had an older age of diabetes onset and higher BMI,Multivariable Cox proportional hazards models (Table 3) showed no association between the Hp genotype and microalbuminuria or macroalbuminuria incidence. Con- versely, adjusting for univariately significant risk factors, an increased risk of an early renal function decline was observed for individuals carrying the Hp 2/2 compared with the Hp 1/1 genotype (hazard ratio 1.79 [95% CI ϭ 1.06 -3.00]). Similarly, the Hp 2/2 conferred over a twofold increased risk of ESRD compared with the Hp 1/1 geno- type (2.45 [1.05-5.73]). The risk associated with the Hp 2/1 reached statistical significance for neither early renal function decline nor ESRD incidence.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>TABLE 2</head><label>2</label><figDesc>Participant characteristics at study entry by a subsequent decline Ն30 ml/min per 1.73 m 2 from baseline eGFR and ESRD A decline Ն30 ml/min per 1.73 m 2 from baseline SD unless otherwise indicated. The sample size for ACE/angiotensin receptor blocker medications was 437 for a decline Ն30 ml/min per 1.73 m 2 from baseline eGFR (251 noncases and 186 incident cases) and 463 for the outcome of ESRD (405 noncases and 58 incident cases). *The Wilcoxon two-sample test was used for nonnormally distributed variables; data are median (interquartile range). †Fisher exact test. ARB, angiotensin receptor blocker.</figDesc><table><row><cell></cell><cell></cell><cell>eGFR</cell><cell></cell><cell></cell><cell>ESRD</cell><cell></cell></row><row><cell></cell><cell>No</cell><cell>Yes</cell><cell>P</cell><cell>No</cell><cell>Yes</cell><cell>P</cell></row><row><cell>n</cell><cell>260</cell><cell>188</cell><cell></cell><cell>416</cell><cell>58</cell><cell></cell></row><row><cell>Age (years)</cell><cell>26.2 Ϯ 8.0</cell><cell>27.8 Ϯ 7.3</cell><cell>0.04</cell><cell>26.6 Ϯ 7.8</cell><cell>31.2 Ϯ 6.3</cell><cell>Ͻ0.0001</cell></row><row><cell>Age at onset (years)</cell><cell>7.9 Ϯ 4.2</cell><cell>9.0 Ϯ 3.8</cell><cell>0.005</cell><cell>8.4 Ϯ 4.1</cell><cell>7.8 Ϯ 3.9</cell><cell>0.29</cell></row><row><cell>Diabetes duration (years)</cell><cell>18.3 Ϯ 7.3</cell><cell>18.8 Ϯ 7.6</cell><cell>0.53</cell><cell>18.2 Ϯ 7.4</cell><cell>23.4 Ϯ 7.1</cell><cell>Ͻ0.0001</cell></row><row><cell>Follow-up time (years)</cell><cell>14.0 Ϯ 5.3</cell><cell>6.5 Ϯ 4.8</cell><cell cols="2">Ͻ0.0001 15.2 Ϯ 3.9</cell><cell>9.1 Ϯ 4.6</cell><cell>Ͻ0.0001</cell></row><row><cell>Female subjects</cell><cell>45.8 (119)</cell><cell>54.3 (102)</cell><cell>0.08</cell><cell>49.5 (206)</cell><cell>48.3 (28)</cell><cell>0.86</cell></row><row><cell>BMI (kg/m 2 )</cell><cell>23.3 Ϯ 3.5</cell><cell>24.3 Ϯ 3.0</cell><cell cols="2">0.0008 23.6 Ϯ 3.3</cell><cell>23.9 Ϯ 3.0</cell><cell>0.48</cell></row><row><cell>Waist-to-hip ratio</cell><cell>0.82 Ϯ 0.07</cell><cell>0.83 Ϯ 0.07</cell><cell>0.47</cell><cell>0.82 Ϯ 0.07</cell><cell>0.84 Ϯ 0.08</cell><cell>0.09</cell></row><row><cell>Ever smokers</cell><cell>33.5 (87)</cell><cell>38.8 (73)</cell><cell>0.24</cell><cell>34.6 (144)</cell><cell>41.4 (24)</cell><cell>0.31</cell></row><row><cell>HbA 1 (%)</cell><cell>8.5 (1.4)</cell><cell>9.0 (1.4)</cell><cell cols="2">0.0004 10.2 (1.7)</cell><cell>10.6 (1.9)</cell><cell>0.11</cell></row><row><cell>Insulin dose per weight*</cell><cell>0.80 (0.62-0.94)</cell><cell>0.77 (0.64-0.94)</cell><cell>0.75</cell><cell>0.80 (0.64-0.94)</cell><cell>0.67 (0.57-0.80)</cell><cell>0.002</cell></row><row><cell>Systolic blood pressure</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>(mmHg)</cell><cell>110.6 Ϯ 12.6</cell><cell>113.4 Ϯ 14.9</cell><cell>0.04</cell><cell>110.7 Ϯ 12.8</cell><cell>123.5 Ϯ 16.5</cell><cell>Ͻ0.0001</cell></row><row><cell>Diastolic blood pressure</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>(mmHg)</cell><cell>71.1 Ϯ 10.5</cell><cell>72.7 Ϯ 10.8</cell><cell>0.10</cell><cell>71.1 Ϯ 10.2</cell><cell>77.9 Ϯ 12.4</cell><cell>0.0001</cell></row><row><cell>Hypertension</cell><cell>9.6 (25)</cell><cell>13.8 (26)</cell><cell>0.17</cell><cell>9.1 (38)</cell><cell>50.0 (29)</cell><cell>Ͻ0.0001</cell></row><row><cell>HDL cholesterol (mg/dl)</cell><cell>55.2 Ϯ 12.4</cell><cell>52.9 Ϯ 11.4</cell><cell>0.05</cell><cell>54.6 Ϯ 12.1</cell><cell>50.2 Ϯ 10.4</cell><cell>0.009</cell></row><row><cell>Non-HDL cholesterol</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>(mg/dl)</cell><cell>127.5 Ϯ 34.2</cell><cell>138.9 Ϯ 44.2</cell><cell cols="2">0.003 128.8 Ϯ 34.9</cell><cell>166.5 Ϯ 57.6</cell><cell>Ͻ0.0001</cell></row><row><cell>ACE/ARB use</cell><cell>1.6 (4)</cell><cell>2.2 (4)</cell><cell>0.47 †</cell><cell>1.5 (6)</cell><cell>13.8 (8)</cell><cell>Ͻ0.0001</cell></row><row><cell cols="2">Serum creatinine (mg/dl)* 0.90 (0.80-1.10)</cell><cell>0.70 (0.60-0.90)</cell><cell cols="2">Ͻ0.0001 0.80 (0.70-1.0)</cell><cell>1.3 (0.90-1.80)</cell><cell>Ͻ0.0001</cell></row><row><cell>eGFR by Cockcroft-Gault</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">(ml/min per 1.73 m 2 ) 105.3 Ϯ 23.4</cell><cell>140.6 Ϯ 42.9</cell><cell cols="2">Ͻ0.0001 121.3 Ϯ 38.0</cell><cell>77.7 Ϯ 40.8</cell><cell>Ͻ0.0001</cell></row><row><cell>AER (g/min)*</cell><cell>10.6 (6.2-31.0)</cell><cell>19.6 (8.8-363.1)</cell><cell cols="2">Ͻ0.0001 11.3 (6.8-46.7)</cell><cell cols="2">1,030.2 (281.5-1,877.8) Ͻ0.0001</cell></row><row><cell>White blood cell count ϫ</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>10 3 /mm 2 *</cell><cell>6.1 (5.2-7.1)</cell><cell>6.2 (5.4-7.6)</cell><cell>0.10</cell><cell>6.1 (5.2-7.2)</cell><cell>7.1 (5.9-8.9)</cell><cell>Ͻ0.0001</cell></row><row><cell>Fibrinogen (mg/dl)*</cell><cell cols="2">250.0 (210.0-310.0) 270.0 (240.0-350.0)</cell><cell cols="2">0.0007 270.0 (220.0-310.0)</cell><cell>310.0 (270.0-390.0)</cell><cell>Ͻ0.0001</cell></row><row><cell>Hp genotype</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>1/1</cell><cell>64.8 (35)</cell><cell>35.2 (19)</cell><cell></cell><cell>87.9 (51)</cell><cell>12.1 (7)</cell><cell></cell></row><row><cell>2/1</cell><cell>62.1 (128)</cell><cell>37.9 (78)</cell><cell></cell><cell>90.2 (193)</cell><cell>9.8 (21)</cell><cell></cell></row><row><cell>2/2</cell><cell>51.6 (97)</cell><cell>48.4 (91)</cell><cell>0.06</cell><cell>85.2 (172)</cell><cell>14.9 (30)</cell><cell>0.29</cell></row><row><cell cols="2">Data are percent (n) or means Ϯ</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>TABLE 3</head><label>3</label><figDesc>Hazard ratios (95% CIs) from Cox proportional hazard models for the incidence of microalbuminuria, macroalbuminuria, eGFR decline (decline Ն30 ml/min per 1.73 m 2 from baseline eGFR), and ESRD allowed for diabetes duration, sex, BMI, log AER, and eGFR Model 2 allowed for variables in model 1 in addition to HbA 1 , systolic blood pressure, and HDL and non-HDL cholesterol Model 3 allowed for variables in model 2 in addition to fibrinogen ESRD (n ϭ 467, 57 incident events)</figDesc><table><row><cell>Outcome</cell><cell>Crude</cell><cell>Model 1</cell><cell>Model 2</cell><cell>Model 3</cell></row><row><cell cols="2">Microalbuminuria (n ϭ 270, 111 incident events)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Hp genotype</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>1/1</cell><cell>Referent</cell><cell>Referent</cell><cell>Referent</cell><cell>Referent</cell></row><row><cell>2/1</cell><cell>2.09 (0.95-4.59)</cell><cell>2.19 (0.996-4.80)</cell><cell>2.08 (0.95-4.56)</cell><cell>1.77 (0.80-3.92)</cell></row><row><cell>2/2</cell><cell>1.84 (0.83-4.07)</cell><cell>1.95 (0.88-4.32)</cell><cell>1.67 (0.75-3.71)</cell><cell>1.34 (0.59-3.05)</cell></row><row><cell>A1C</cell><cell>1,147.803</cell><cell>1,140.392</cell><cell>1,106.418</cell><cell>1,100.600</cell></row><row><cell cols="3">Model 1 allowed for diabetes duration, sex, log AER, and eGFR</cell><cell></cell><cell></cell></row><row><cell cols="5">Model 2 allowed for variables in model 1 in addition to HbA 1 , systolic blood pressure, and HDL and non-HDL cholesterol</cell></row><row><cell cols="3">Model 3 allowed for variables in model 2 in addition to white blood cell count</cell><cell></cell><cell></cell></row><row><cell cols="2">Macroalbuminuria (n ϭ 364, 61 incident events)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Hp genotype</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>1/1</cell><cell>Referent</cell><cell>Referent</cell><cell>Referent</cell><cell>Referent</cell></row><row><cell>2/1</cell><cell>0.77 (0.35-1.70)</cell><cell>0.78 (0.35-1.72)</cell><cell>0.77 (0.35-1.72)</cell><cell>0.72 (0.33-1.60)</cell></row><row><cell>2/2</cell><cell>0.84 (0.38-1.86)</cell><cell>0.78 (0.35-1.72)</cell><cell>0.78 (0.35-1.73)</cell><cell>0.73 (0.33-1.62)</cell></row><row><cell>A1C</cell><cell>686.874</cell><cell>656.057</cell><cell>640.020</cell><cell>636.806</cell></row><row><cell cols="4">Model 1 allowed for diabetes duration, sex, smoking status, waist-to-hip ratio, log AER, and eGFR</cell><cell></cell></row><row><cell cols="5">Model 2 allowed for variables in model 1 in addition to HbA 1 , systolic blood pressure, and HDL and non-HDL cholesterol</cell></row><row><cell cols="3">Model 3 allowed for variables in model 2 in addition to white blood cell count</cell><cell></cell><cell></cell></row><row><cell cols="3">A decline Ն30 ml/min per 1.73 m 2 from baseline eGFR (n ϭ 441, 187 incident events)</cell><cell></cell><cell></cell></row><row><cell>Hp genotype</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>1/1</cell><cell>Referent</cell><cell>Referent</cell><cell>Referent</cell><cell>Referent</cell></row><row><cell>2/2</cell><cell>1.59 (0.97-2.60)</cell><cell>1.30 (0.78-2.18)</cell><cell>1.38 (0.82-2.31)</cell><cell>1.38 (0.82-2.31)</cell></row><row><cell>2/2</cell><cell>1.59 (0.97-2.60)</cell><cell>1.64 (0.99-2.73)</cell><cell>1.79 (1.06-3.00)</cell><cell>1.79 (1.06-3.00)</cell></row><row><cell>A1C</cell><cell>2,102.198</cell><cell>1,897.376</cell><cell>1,896.567</cell><cell>1,896.567</cell></row><row><cell>Model 1 Hp genotype</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>1/1</cell><cell>Referent</cell><cell>Referent</cell><cell>Referent</cell><cell>Referent</cell></row><row><cell>2/1</cell><cell>0.72 (0.30-1.69)</cell><cell>1.14 (0.48-2.74)</cell><cell>1.24 (0.51-2.98)</cell><cell>1.32 (0.55-3.16)</cell></row><row><cell>2/2</cell><cell>1.15 (0.50-2.61)</cell><cell>2.17 (0.93-5.04)</cell><cell>2.74 (1.17-6.45)</cell><cell>2.45 (1.05-5.73)</cell></row><row><cell>A1C</cell><cell>672.450</cell><cell>522.184</cell><cell>509.657</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>TABLE 4</head><label>4</label><figDesc>Incidence of renal outcomes by Hp genotype</figDesc><table><row><cell></cell><cell></cell><cell></cell><cell>Hp genotype</cell><cell></cell><cell></cell></row><row><cell>Outcome incidence</cell><cell>n</cell><cell>1/1</cell><cell>2/1</cell><cell>2/2</cell><cell>P</cell></row><row><cell>Microalbuminuria</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Diabetes diagnosis Յ1965</cell><cell>73</cell><cell>11.1 (1)</cell><cell>46.3 (19)</cell><cell>47.8 (11)</cell><cell>0.14*</cell></row><row><cell>Diabetes diagnosis Ͼ1965</cell><cell>201</cell><cell>27.3 (6)</cell><cell>43.7 (38)</cell><cell>39.1 (36)</cell><cell>0.37</cell></row><row><cell>Total cohort</cell><cell>274</cell><cell>22.6 (7)</cell><cell>44.5 (57)</cell><cell>40.9 (47)</cell><cell>0.08</cell></row><row><cell>Cumulative incidence</cell><cell>483</cell><cell>59.3 (35)</cell><cell>67.1 (145)</cell><cell>67.3 (140)</cell><cell>0.49</cell></row><row><cell>Macroalbuminuria</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Diabetes diagnosis Յ1965</cell><cell>112</cell><cell>0.0 (0)</cell><cell>17.5 (11)</cell><cell>24.3 (9)</cell><cell>0.16*</cell></row><row><cell>Diabetes diagnosis Ͼ1965</cell><cell>259</cell><cell>25.8 (8)</cell><cell>13.9 (15)</cell><cell>15.8 (19)</cell><cell>0.28</cell></row><row><cell>Total cohort</cell><cell>371</cell><cell>18.6 (8)</cell><cell>15.2 (26)</cell><cell>17.8 (28)</cell><cell>0.77</cell></row><row><cell>Cumulative incidence</cell><cell>483</cell><cell>40.7 (24)</cell><cell>32.9 (71)</cell><cell>38.0 (79)</cell><cell>0.40</cell></row><row><cell>Early renal function decline</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Diabetes diagnosis Յ1965</cell><cell>145</cell><cell>47.1 (8)</cell><cell>34.3 (25)</cell><cell>50.9 (28)</cell><cell>0.15</cell></row><row><cell>Diabetes diagnosis Ͼ1965</cell><cell>303</cell><cell>29.7 (11)</cell><cell>39.9 (53)</cell><cell>47.4 (63)</cell><cell>0.13</cell></row><row><cell>Total cohort</cell><cell>448</cell><cell>35.2 (19)</cell><cell>37.9 (78)</cell><cell>48.4 (91)</cell><cell>0.06</cell></row><row><cell>ESRD</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Diabetes diagnosis Յ1965</cell><cell>162</cell><cell>22.2 (4)</cell><cell>17.7 (14)</cell><cell>27.7 (18)</cell><cell>0.33*</cell></row><row><cell>Diabetes diagnosis Ͼ1965</cell><cell>312</cell><cell>7.5 (3)</cell><cell>5.2 (7)</cell><cell>8.8 (12)</cell><cell>0.50*</cell></row><row><cell>Total cohort</cell><cell>474</cell><cell>12.1 (7)</cell><cell>9.8 (21)</cell><cell>14.9 (30)</cell><cell>0.29</cell></row><row><cell>Cumulative incidence</cell><cell>483</cell><cell>13.6 (8)</cell><cell>10.7 (23)</cell><cell>17.3 (36)</cell><cell>0.14</cell></row></table><note>Data are percent (n) unless otherwise indicated. *Fisher exact test.</note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">diabetes.diabetesjournals.org DIABETES, VOL. 58, DECEMBER 2009</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">DIABETES, VOL. 58, DECEMBER 2009 diabetes.diabetesjournals.org</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACKNOWLEDGMENTS</head><p>This research was supported by the National Institutes of Health Grant DK34818.</p><p>No potential conflicts of interest relevant to this article were reported.</p><p>We thank all study participants for their invaluable contributions as well as the Epidemiology of Diabetes Complications Study staff.</p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Role of oxidative stress in diabetic complications: a new perspective on an old paradigm</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">W</forename><surname>Baynes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">R</forename><surname>Thorpe</surname></persName>
		</author>
		<idno type="DOI">10.2337/diabetes.48.1.1</idno>
		<idno type="PMID">9892215</idno>
	</analytic>
	<monogr>
		<title level="j">Diabetes</title>
		<title level="j" type="abbrev">Diabetes</title>
		<idno type="ISSN">0012-1797</idno>
		<idno type="ISSNe">1939-327X</idno>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="1" to="9" />
			<date type="published" when="1999-01-01" />
			<publisher>American Diabetes Association</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Effects of Vitamin E on Cardiovascular and Microvascular Outcomes in High-Risk Patients With Diabetes: Results of the HOPE Study and MICRO-HOPE Substudy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Lonn</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Yusuf</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Hoogwerf</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Pogue</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Q</forename><surname>Yi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Zinman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Bosch</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Dagenais</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">F E</forename><surname>Mann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">C</forename><surname>Gerstein</surname></persName>
		</author>
		<idno type="DOI">10.2337/diacare.25.11.1919</idno>
		<idno type="PMID">12401733</idno>
		<ptr type="open-access" target="http://care.diabetesjournals.org/content/25/11/1919.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Diabetes Care</title>
		<title level="j" type="abbrev">Diabetes Care</title>
		<idno type="ISSN">0149-5992</idno>
		<idno type="ISSNe">1935-5548</idno>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1919" to="1927" />
			<date type="published" when="2002-11-01" />
			<publisher>American Diabetes Association</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Application of pharmacogenomics in the prevention of diabetic cardiovascular disease: Mechanistic basis and clinical evidence for utilization of the haptoglobin genotype in determining benefit from antioxidant therapy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andrew</forename><forename type="middle">P</forename><surname>Levy</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.pharmthera.2006.05.002</idno>
		<idno type="PMID">16854468</idno>
	</analytic>
	<monogr>
		<title level="j">Pharmacology &amp; Therapeutics</title>
		<title level="j" type="abbrev">Pharmacology &amp; Therapeutics</title>
		<idno type="ISSN">0163-7258</idno>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="501" to="512" />
			<date type="published" when="2006-11" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Biological and clinical significance of haptoglobin polymorphism in humans</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">R</forename><surname>Langlois</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">R</forename><surname>Delanghe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chem</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="1589" to="1600" />
			<date type="published" when="1996" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Identification of the haemoglobin scavenger receptor</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mette</forename><surname>Kristiansen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jonas</forename><forename type="middle">H</forename><surname>Graversen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christian</forename><surname>Jacobsen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ole</forename><surname>Sonne</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hans-Jürgen</forename><surname>Hoffman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">K Alex</forename><surname>Law</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Søren</forename><forename type="middle">K</forename><surname>Moestrup</surname></persName>
		</author>
		<idno type="DOI">10.1038/35051594</idno>
		<idno type="PMID">11196644</idno>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<title level="j" type="abbrev">Nature</title>
		<idno type="ISSN">0028-0836</idno>
		<idno type="ISSNe">1476-4687</idno>
		<imprint>
			<biblScope unit="volume">409</biblScope>
			<biblScope unit="issue">6817</biblScope>
			<biblScope unit="page" from="198" to="201" />
			<date type="published" when="2001-01" />
			<publisher>Springer Nature America, Inc</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">In vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rabea</forename><surname>Asleh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andrew</forename><forename type="middle">P</forename><surname>Levy</surname></persName>
		</author>
		<idno type="DOI">10.2147/vhrm.1.1.19.58930</idno>
		<idno type="PMID">17319095</idno>
		<idno type="PMCID">PMC1993923</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc1993923?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">Vascular Health and Risk Management</title>
		<title level="j" type="abbrev">vhrm</title>
		<idno type="ISSN">1176-6344</idno>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="19" to="28" />
			<date type="published" when="2005" />
			<publisher>Dove Medical Press Ltd.</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Genetically Determined Heterogeneity in Hemoglobin Scavenging and Susceptibility to Diabetic Cardiovascular Disease</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rabea</forename><surname>Asleh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Stuart</forename><surname>Marsh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mark</forename><surname>Shilkrut</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ofer</forename><surname>Binah</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Julia</forename><surname>Guetta</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Flavio</forename><surname>Lejbkowicz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ben</forename><surname>Enav</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Naim</forename><surname>Shehadeh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yoram</forename><surname>Kanter</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Orit</forename><surname>Lache</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Osher</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nina</forename><forename type="middle">S</forename><surname>Levy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andrew</forename><forename type="middle">P</forename><surname>Levy</surname></persName>
		</author>
		<idno type="DOI">10.1161/01.res.0000076889.23082.f1</idno>
		<idno type="PMID">12750308</idno>
		<ptr type="open-access" target="https://www.ahajournals.org/doi/pdf/10.1161/01.RES.0000076889.23082.F1" />
	</analytic>
	<monogr>
		<title level="j">Circulation Research</title>
		<title level="j" type="abbrev">Circulation Research</title>
		<idno type="ISSN">0009-7330</idno>
		<idno type="ISSNe">1524-4571</idno>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1193" to="1200" />
			<date type="published" when="2003-06-13" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Haptoglobin Genotype– and Diabetes-Dependent Differences in Iron-Mediated Oxidative Stress In Vitro and In Vivo</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rabea</forename><surname>Asleh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Julia</forename><surname>Guetta</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shiri</forename><surname>Kalet-Litman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rachel</forename><surname>Miller-Lotan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andrew</forename><forename type="middle">P</forename><surname>Levy</surname></persName>
		</author>
		<idno type="DOI">10.1161/01.res.0000156653.05853.b9</idno>
		<idno type="PMID">15662028</idno>
		<ptr type="open-access" target="https://www.ahajournals.org/doi/pdf/10.1161/01.RES.0000156653.05853.b9" />
	</analytic>
	<monogr>
		<title level="j">Circulation Research</title>
		<title level="j" type="abbrev">Circulation Research</title>
		<idno type="ISSN">0009-7330</idno>
		<idno type="ISSNe">1524-4571</idno>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="435" to="441" />
			<date type="published" when="2005-03-04" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Downregulation of the Hb scavenger receptor in individuals with diabetes and the Hp 2-2 genotype: implications for the response to intraplaque hemorrhage and plaque vulnerability</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">P</forename><surname>Levy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">R</forename><surname>Purushothaman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">S</forename><surname>Levy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Purushothaman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Strauss</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Asleh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Marsh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">K</forename><surname>Moestrup</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">J</forename><surname>Moller</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">A</forename><surname>Zias</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Benhayon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Fuster</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">R</forename><surname>Moreno</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circ Res</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="page" from="106" to="110" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Haptoglobin Genotype Is a Regulator of Reverse Cholesterol Transport in Diabetes In Vitro and In Vivo</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Asleh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Miller-Lotan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Aviram</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Hayek</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Yulish</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">E</forename><surname>Levy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Blum</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">U</forename><surname>Milman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Shapira</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">P</forename><surname>Levy</surname></persName>
		</author>
		<idno type="DOI">10.1161/01.res.0000251741.65179.56</idno>
		<idno type="PMID">17082477</idno>
		<ptr type="open-access" target="https://www.ahajournals.org/doi/pdf/10.1161/01.RES.0000251741.65179.56" />
	</analytic>
	<monogr>
		<title level="j">Circulation Research</title>
		<title level="j" type="abbrev">Circulation Research</title>
		<idno type="ISSN">0009-7330</idno>
		<idno type="ISSNe">1524-4571</idno>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1419" to="1425" />
			<date type="published" when="2006-12-08" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andrew</forename><forename type="middle">P</forename><surname>Levy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Irit</forename><surname>Hochberg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kathleen</forename><surname>Jablonski</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Helaine</forename><forename type="middle">E</forename><surname>Resnick</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Elisa</forename><forename type="middle">T</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lyle</forename><surname>Best</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Barbara</forename><forename type="middle">V</forename><surname>Howard</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0735-1097(02)02534-2</idno>
		<idno type="PMID">12475459</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of the American College of Cardiology</title>
		<title level="j" type="abbrev">Journal of the American College of Cardiology</title>
		<idno type="ISSN">0735-1097</idno>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1984" to="1990" />
			<date type="published" when="2002-12" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Haptoglobin Polymorphism Predicts 30-Day Mortality and Heart Failure in Patients With Diabetes and Acute Myocardial Infarction</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Suleiman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Aronson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Asleh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">R</forename><surname>Kapeliovich</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Roguin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">R</forename><surname>Meisel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Shochat</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Sulieman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">A</forename><surname>Reisner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Markiewicz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Hammerman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Lotan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">S</forename><surname>Levy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">P</forename><surname>Levy</surname></persName>
		</author>
		<idno type="DOI">10.2337/diabetes.54.9.2802</idno>
		<idno type="PMID">16123372</idno>
		<ptr type="open-access" target="http://diabetes.diabetesjournals.org/content/54/9/2802.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Diabetes</title>
		<title level="j" type="abbrev">Diabetes</title>
		<idno type="ISSN">0012-1797</idno>
		<idno type="ISSNe">1939-327X</idno>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="2802" to="2806" />
			<date type="published" when="2005-08-25" />
			<publisher>American Diabetes Association</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">The Effect of Vitamin E Supplementation on Cardiovascular Risk in Diabetic Individuals With Different Haptoglobin Phenotypes</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">P</forename><surname>Levy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">C</forename><surname>Gerstein</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Miller-Lotan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Ratner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Mcqueen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Lonn</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Pogue</surname></persName>
		</author>
		<idno type="DOI">10.2337/diacare.27.11.2767</idno>
		<idno type="PMID">15505023</idno>
		<ptr type="open-access" target="http://care.diabetesjournals.org/content/27/11/2767.1.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Diabetes Care</title>
		<title level="j" type="abbrev">Diabetes Care</title>
		<idno type="ISSN">0149-5992</idno>
		<idno type="ISSNe">1935-5548</idno>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="2767" to="2767" />
			<date type="published" when="2004-10-25" />
			<publisher>American Diabetes Association</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Vitamin E Supplementation Reduces Cardiovascular Events in a Subgroup of Middle-Aged Individuals With Both Type 2 Diabetes Mellitus and the Haptoglobin 2-2 Genotype: A Prospective Double-Blinded Clinical Trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">U</forename><surname>Milman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Blum</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Shapira</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Aronson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Miller-Lotan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Anbinder</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Alshiek</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Bennett</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Kostenko</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Landau</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Keidar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Levy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Khemlin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Radan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">P</forename><surname>Levy</surname></persName>
		</author>
		<idno type="DOI">10.1161/atvbaha.107.153965</idno>
		<idno type="PMID">18032779</idno>
		<ptr type="open-access" target="https://www.ahajournals.org/doi/pdf/10.1161/ATVBAHA.107.153965" />
	</analytic>
	<monogr>
		<title level="j">Arteriosclerosis, Thrombosis, and Vascular Biology</title>
		<title level="j" type="abbrev">Arteriosclerosis, Thrombosis, and Vascular Biology</title>
		<idno type="ISSN">1079-5642</idno>
		<idno type="ISSNe">1524-4636</idno>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="341" to="347" />
			<date type="published" when="2007-11-15" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Haptoglobin Genotype: A Determinant of Cardiovascular Complication Risk in Type 1 Diabetes</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Costacou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">E</forename><surname>Ferrell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">J</forename><surname>Orchard</surname></persName>
		</author>
		<idno type="DOI">10.2337/db08-0095</idno>
		<idno type="PMID">18332093</idno>
	</analytic>
	<monogr>
		<title level="j">Diabetes</title>
		<title level="j" type="abbrev">Diabetes</title>
		<idno type="ISSN">0012-1797</idno>
		<idno type="ISSNe">1939-327X</idno>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1702" to="1706" />
			<date type="published" when="2008-03-10" />
			<publisher>American Diabetes Association</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Prevalence of Complications in IDDM by Sex and Duration: Pittsburgh Epidemiology of Diabetes Complications Study II</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">J</forename><surname>Orchard</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">S</forename><surname>Dorman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">E</forename><surname>Maser</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">J</forename><surname>Becker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">L</forename><surname>Drash</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Ellis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">E</forename><surname>Laporte</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">H</forename><surname>Kuller</surname></persName>
		</author>
		<idno type="DOI">10.2337/diab.39.9.1116</idno>
		<idno type="PMID">2384191</idno>
	</analytic>
	<monogr>
		<title level="j">Diabetes</title>
		<title level="j" type="abbrev">Diabetes</title>
		<idno type="ISSN">0012-1797</idno>
		<idno type="ISSNe">1939-327X</idno>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1116" to="1124" />
			<date type="published" when="1990-09-01" />
			<publisher>American Diabetes Association</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">The Pittsburgh Study of Insulin-Dependent Diabetes Mellitus: Risk for Diabetes Among Relatives of IDDM</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">K</forename><surname>Wagener</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Sacks</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">E</forename><surname>Laporte</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Macgregor</surname></persName>
		</author>
		<idno type="DOI">10.2337/diab.31.2.136</idno>
		<idno type="PMID">6759229</idno>
	</analytic>
	<monogr>
		<title level="j">Diabetes</title>
		<title level="j" type="abbrev">Diabetes</title>
		<idno type="ISSN">0012-1797</idno>
		<idno type="ISSNe">1939-327X</idno>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="136" to="144" />
			<date type="published" when="1982-02-01" />
			<publisher>American Diabetes Association</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">The hypertension detection and follow-up program</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">O</forename><surname>Borhani</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">H</forename><surname>Kass</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">G</forename><surname>Langford</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">H</forename><surname>Payne</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">D</forename><surname>Remington</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Stamler</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Hdfp Cooperative</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Group</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Prev Med</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="207" to="215" />
			<date type="published" when="1976" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Heparin-Mn2ϩ quantitation of high-densitylipoprotein cholesterol: an ultrafiltration procedure for lipemic samples</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">R</forename><surname>Warnick</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">J</forename><surname>Albers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chem</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="900" to="904" />
			<date type="published" when="1978" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Enzymatic determination of total serum cholesterol</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">C</forename><surname>Allain</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">S</forename><surname>Poon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">S</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Richmond</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">C</forename><surname>Fu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chem</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="470" to="475" />
			<date type="published" when="1974" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Quantitative determination of serum triglycerides by the use of enzymes</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Bucolo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>David</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chem</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="476" to="482" />
			<date type="published" when="1973" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">A new approach to the evaluation of proteinuric states</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Ellis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">J</forename><surname>Buffone</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chem</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="666" to="670" />
			<date type="published" when="1977" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Choice of Urine Sample Predictive of Microalbuminuria in Patients With Insulin-Dependent Diabetes Mellitus</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Demetrius</forename><surname>Ellis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Beth</forename><forename type="middle">Ann</forename><surname>Coonrod</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Janice</forename><forename type="middle">S</forename><surname>Dorman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sheryl</forename><forename type="middle">F</forename><surname>Kelsey</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dorothy</forename><forename type="middle">J</forename><surname>Becker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ellis</forename><forename type="middle">D</forename><surname>Avner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Trevor</forename><forename type="middle">J</forename><surname>Orchard</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0272-6386(89)80039-3</idno>
		<idno type="PMID">2705450</idno>
	</analytic>
	<monogr>
		<title level="j">American Journal of Kidney Diseases</title>
		<title level="j" type="abbrev">American Journal of Kidney Diseases</title>
		<idno type="ISSN">0272-6386</idno>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="321" to="328" />
			<date type="published" when="1989-04" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Prediction of Creatinine Clearance from Serum Creatinine</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Donald</forename><forename type="middle">W</forename><surname>Cockcroft</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Henry</forename><surname>Gault</surname></persName>
		</author>
		<idno type="DOI">10.1159/000180580</idno>
		<idno type="PMID">1244564</idno>
	</analytic>
	<monogr>
		<title level="j">Nephron</title>
		<title level="j" type="abbrev">Nephron</title>
		<idno type="ISSN">0028-2766</idno>
		<idno type="ISSNe">1423-0186</idno>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="31" to="41" />
			<date type="published" when="1976" />
			<publisher>S. Karger AG</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Genotyping of the common haptoglobin Hp 1/2 polymorphism based on PCR</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Koch</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Latz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Eichinger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Roguin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">P</forename><surname>Levy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Schö Mig</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Kastrati</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chem</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="1377" to="1382" />
			<date type="published" when="2002" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Clinical results of a rapid screening assay for haptoglobin 2-2: a cardiovascular disease risk marker in diabetes (Abstract)</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Victor</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Cheong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jjs</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Levy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Miller-Lotan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">P</forename><surname>Levy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Blum</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">J</forename><surname>Orchard</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">W</forename><surname>Evans</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Costacou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">A</forename><surname>Hauth</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page">176</biblScope>
			<date type="published" when="2009" />
		</imprint>
	</monogr>
	<note>Suppl. 1</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Haptoglobin Phenotype and Vascular Complications in Patients with Diabetes</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andrew</forename><forename type="middle">P</forename><surname>Levy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ariel</forename><surname>Roguin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Irit</forename><surname>Hochberg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Paula</forename><surname>Herer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Stuart</forename><surname>Marsh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Farid</forename><forename type="middle">M</forename><surname>Nakhoul</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Karl</forename><surname>Skorecki</surname></persName>
		</author>
		<idno type="DOI">10.1056/nejm200009283431313</idno>
		<idno type="PMID">11012324</idno>
	</analytic>
	<monogr>
		<title level="j">New England Journal of Medicine</title>
		<title level="j" type="abbrev">N Engl J Med</title>
		<idno type="ISSN">0028-4793</idno>
		<idno type="ISSNe">1533-4406</idno>
		<imprint>
			<biblScope unit="volume">343</biblScope>
			<biblScope unit="issue">13</biblScope>
			<biblScope unit="page" from="969" to="970" />
			<date type="published" when="2000-09-28" />
			<publisher>New England Journal of Medicine (NEJM/MMS)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Association between Haptoglobin Gene Variants and Diabetic Nephropathy: Haptoglobin Polymorphism in Nephropathy Susceptibility</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bryan</forename><forename type="middle">R</forename><surname>Conway</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">A</forename><surname>Savage</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hugh</forename><forename type="middle">R</forename><surname>Brady</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alexander</forename><forename type="middle">P</forename><surname>Maxwell</surname></persName>
		</author>
		<idno type="DOI">10.1159/000098563</idno>
		<idno type="PMID">17220636</idno>
	</analytic>
	<monogr>
		<title level="j">Nephron Experimental Nephrology</title>
		<title level="j" type="abbrev">Nephron Exp Nephrol</title>
		<idno type="ISSN">1660-2129</idno>
		<imprint>
			<biblScope unit="volume">105</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="e75" to="e79" />
			<date type="published" when="2007" />
			<publisher>S. Karger AG</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Haptoglobin genotype and diabetic microangiopathies in Japanese diabetic patients</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Koda</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Soejima</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Yamagishi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Amano</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Okamoto</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Inagaki</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Yamada</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Kimura</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00125-002-0834-5</idno>
		<idno type="PMID">12187922</idno>
		<idno type="ark">ark:/67375/VQC-8DBBR509-5</idno>
		<idno type="istexId">4D4656849ACC57D06A72C7280CB35E2288F9296A</idno>
	</analytic>
	<monogr>
		<title level="j">Diabetologia</title>
		<title level="j" type="abbrev">Diabetologia</title>
		<idno type="ISSN">0012-186X</idno>
		<idno type="ISSNe">1432-0428</idno>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1039" to="1040" />
			<date type="published" when="2002-04-26" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Urinary measurement of transforming growth factor-␤ and type IV collagen as new markers of renal injury: application in diabetic nephropathy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Ellis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">Y</forename><surname>Forrest</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Erbey</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">J</forename><surname>Orchard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chem</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="950" to="956" />
			<date type="published" when="1998" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Renal Insufficiency in the Absence of Albuminuria and Retinopathy Among Adults With Type 2 Diabetes Mellitus</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Holly</forename><forename type="middle">J</forename><surname>Kramer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Q</forename><forename type="middle">D</forename><surname>Nguyen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Curhan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">Y</forename><surname>Hsu</surname></persName>
		</author>
		<idno type="DOI">10.1001/jama.289.24.3273</idno>
		<idno type="PMID">12824208</idno>
		<ptr type="open-access" target="https://jamanetwork.com/journals/jama/articlepdf/196801/JOC22096.pdf" />
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<title level="j" type="abbrev">JAMA</title>
		<idno type="ISSN">0098-7484</idno>
		<imprint>
			<biblScope unit="volume">289</biblScope>
			<biblScope unit="issue">24</biblScope>
			<biblScope unit="page">3273</biblScope>
			<date type="published" when="2003-06-25" />
			<publisher>American Medical Association (AMA)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Risk Factors for Renal Dysfunction in Type 2 Diabetes: U.K. Prospective Diabetes Study 74</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Retnakaran</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">A</forename><surname>Cull</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">I</forename><surname>Thorne</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">I</forename><surname>Adler</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">R</forename><surname>Holman</surname></persName>
		</author>
		<idno type="DOI">10.2337/db05-1620</idno>
		<idno type="PMID">16731850</idno>
		<ptr type="open-access" target="http://diabetes.diabetesjournals.org/content/55/6/1832.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Diabetes</title>
		<title level="j" type="abbrev">Diabetes</title>
		<idno type="ISSN">0012-1797</idno>
		<idno type="ISSNe">1939-327X</idno>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1832" to="1839" />
			<date type="published" when="2006-05-26" />
			<publisher>American Diabetes Association</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Sequence of Progression of Albuminuria and Decreased GFR in Persons With Type 1 Diabetes: A Cohort Study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tina</forename><surname>Costacou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Demetrius</forename><surname>Ellis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Linda</forename><surname>Fried</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Trevor</forename><forename type="middle">J</forename><surname>Orchard</surname></persName>
		</author>
		<idno type="DOI">10.1053/j.ajkd.2007.08.005</idno>
		<idno type="PMID">17954285</idno>
	</analytic>
	<monogr>
		<title level="j">American Journal of Kidney Diseases</title>
		<title level="j" type="abbrev">American Journal of Kidney Diseases</title>
		<idno type="ISSN">0272-6386</idno>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="721" to="732" />
			<date type="published" when="2007-11" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Pharmacogenomic effect of vitamin E on kidney structure and function in transgenic mice with the haptoglobin 2-2 genotype and diabetes mellitus</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Farid</forename><forename type="middle">M</forename><surname>Nakhoul</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rachel</forename><surname>Miller-Lotan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hoda</forename><surname>Awad</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rabea</forename><surname>Asleh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kheir</forename><surname>Jad</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nakhoul</forename><surname>Nakhoul</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Roy</forename><surname>Asaf</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Niroz</forename><surname>Abu-Saleh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andrew</forename><forename type="middle">P</forename><surname>Levy</surname></persName>
		</author>
		<idno type="DOI">10.1152/ajprenal.90655.2008</idno>
		<idno type="PMID">19176700</idno>
		<ptr type="open-access" target="http://pdfs.semanticscholar.org/82d2/7ea586e93d9e970cb4b62ebe30f24b939816.pdf" />
	</analytic>
	<monogr>
		<title level="j">American Journal of Physiology-Renal Physiology</title>
		<title level="j" type="abbrev">American Journal of Physiology-Renal Physiology</title>
		<idno type="ISSN">1931-857X</idno>
		<idno type="ISSNe">1522-1466</idno>
		<imprint>
			<biblScope unit="volume">296</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="F830" to="F838" />
			<date type="published" when="2009-04" />
			<publisher>American Physiological Society</publisher>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
